PRINCETON, N.J., and PARIS, Sept. 20, 2010-Medical device pioneer Stentys announced today that results of its completed ‘APPOSITION II’ international randomized clinical trial will be disclosed at “TCT 2010" during a Breakfast Meeting - “Defeating Malapposition: Stentys® Self-Apposing Stents for Safer Treatment of AMI and Complex Coronary Disease” - on Wednesday, Sept. 22nd, from 7:00-8:00 a.m. ET, Room 143A, Level 1, Washington Convention Center.
To register to attend the breakfast meeting and learn of the APPOSITION II clinical trial results, go to www.one-stop-registration.com/tct2010ss, or send your name and contact details to TCT@Laser-Registration.com.
The Stentys stent features a major breakthrough compared to conventional stents: it is self-apposing, i.e., it “fits snugly” into the contour of a blood vessel, behaving as a spring once implanted; its shape and diameter adapt to the anatomic changes of the coronary arteries during the post-AMI phase. By being in permanent contact with the vessel wall, the Stentys stent avoids malapposition (“loosely” fit stent) observed with conventional stents, which puts the patient at significant risk of potential fatal complications such as implant blockage (in-stent thrombosis).
About Stentys
Based in Princeton, N.J., and Paris, Stentys has developed a new generation of stents for the treatment of acute myocardial infarction. Founded by Jacques Séguin, M.D., Ph.D., (founder of CoreValve, which was acquired last year by Medtronic for $700 million) and by Gonzague Issenmann, Stentys received CE Mark of its flagship products in 2010 and has started the pre-release phase in selected European countries. Institutional shareholders are Sofinnova Partners, Crédit Agricole Private Equity and Scottish Equity Partners.
